Paradigm Biopharmaceuticals Limited Stock
Equities
PAR
AU000000PAR5
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.27 AUD | -5.26% | -5.26% | -36.47% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 94.76M 145M |
---|---|---|---|---|---|
Net income 2024 * | -52M -79.61M | Net income 2025 * | 12M 18.37M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.51
x | P/E ratio 2025 * |
6.92
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.7% |
1 day | -5.26% | ||
1 week | -5.26% | ||
Current month | -21.74% | ||
1 month | -20.59% | ||
3 months | -21.74% | ||
6 months | -55.74% | ||
Current year | -36.47% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Abby Macnish
DFI | Director of Finance/CFO | - | 22-08-29 |
Jill Forrest
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Donna Skerrett
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
Paul Rennie
CEO | Chief Executive Officer | - | 14-05-01 |
Amos Meltzer
BRD | Director/Board Member | 58 | 20-12-08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 7 M€ | +0.11% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.27 | -5.26% | 455,715 |
24-04-24 | 0.285 | 0.00% | 311,490 |
24-04-23 | 0.285 | 0.00% | 122,248 |
24-04-22 | 0.285 | 0.00% | 262,619 |
24-04-19 | 0.285 | 0.00% | 481,103 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-36.47% | 65.06M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- PAR Stock